MYL : NASDAQ : Health Care
$37.44 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 5918400.0
04/26/17 - 4:00 PM ET

Financial Analysis


MYLAN NV's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.91 which shows a lack of ability to cover short-term cash needs. The liquidity decreased from the same period a year ago, despite already having weak liquidity to begin with. This would indicate deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 13.84% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)3267.82490.7
EBITDA ($mil)1099.7799.9
EBIT ($mil)673.0490.5
Net Income ($mil)417.5194.6


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)1260.21396.6
Total Assets ($mil)34726.222267.7
Total Debt ($mil)15472.67295.6
Equity ($mil)11116.29764.4


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin56.6258.4
EBITDA Margin33.6532.11
Operating Margin20.5919.69
Sales Turnover0.320.42
Return on Assets1.383.8
Return on Equity4.318.68
Debt Q4 FY16 Q4 FY15
Current Ratio1.491.57
Debt/Capital0.580.43
Interest Expense138.746.4
Interest Coverage4.8510.57


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)535.33490.62
Div / share0.00.0
EPS0.780.38
Book value / share20.7719.9
Institutional Own % n/a n/a
Avg Daily Volume5806167.05820344.0

Valuation


HOLD. MYLAN NV's P/E ratio indicates a discount compared to an average of 43.90 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 24.92. To use another comparison, its price-to-book ratio of 1.79 indicates a discount versus the S&P 500 average of 2.99 and a significant discount versus the industry average of 13.69. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MYL 40.75 Peers 43.90   MYL 9.70 Peers 18.53

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

MYL is trading at a valuation on par with its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MYL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MYL 6.48 Peers 14.49   MYL 0.09 Peers 1.33

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MYL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MYL 1.79 Peers 13.69   MYL -45.19 Peers -1.54

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MYL is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MYL 1.79 Peers 15.95   MYL 17.47 Peers 4.95

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MYL is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MYL has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades